# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Neutral and maintains $5 p...
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate o...
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor ...
-SEC Filing
JMP Securities analyst Reni Benjamin initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform ratin...
HC Wainwright & Co. analyst Robert Burns downgrades Prelude Therapeutics (NASDAQ:PRLD) from Buy to Neutral and announces...
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept...